explore -WSS

explore

author：leisure time 2025-10-06 14:52:57 - browse：3

Obesity conference attendees with a pink and blue Wegovy sign hanging from the ceiling above. -- obesity coverage from STAT — Wegovy, the obesity drug, was inescapable at the ObesityWeek conference in Dallas. Elaine Chen

DALLAS — Here at ObesityWeek, one of the largest conferences on obesity, Novo Nordisk and Eli Lilly are displaying more than a dozen studies that together carry the message: Our blockbuster weight loss treatments will be worth it for society.

But experts point out that much of this company-funded research does not include the cost of the drugs themselves, which sell at more than $10,000 per year in the U.S. and are meant to be taken indefinitely.

The two major pharmaceutical companies have seen interest skyrocket for their GLP-1-based drugs like Ozempic, Wegovy, and Mounjaro, a new generation of medications that can cut substantial amounts of weight. But insurance plans have been slow to grant wide access to obesity treatments, concerned that the vast amount of people eligible to take them, along with their high price, could lead to significant financial strain.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： Alabama IVF ruling threatens families facing fatal genetic disease

focus

knowledge

WSS

Ed Silverman on new gene therapies, biosimilars, coffee, and more

There should be a 'Moonshot' or 'Warp Speed' for rare diseases

Neurocrine Biosciences, biotech based in San Diego, joins PhRMA

Alabama IVF ruling threatens families facing fatal genetic disease

Using force crossed my mind when examining a defiant young patient

Neuroscience renaissance leads to new crop of psychiatric drugs

hotspot

explore

hotspot

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Readout Newsletter: Beam, Prozac, "TechBio" and more

At least 13 dead in Texas as scorching temps continue

He's a Nobel laureate. Critics say he was misleading on Covid

Dobbs anniversary: the lost opportunity of abortion as health care

There should be a 'Moonshot' or 'Warp Speed' for rare diseases

Medicare details structure of new drug price negotiation program

STAT Madness 2024: Meet the contenders

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Color Health wants to make cancer screenings convenient

hotspot

Annovis Bio delivers candor, but not confidence, on Parkinson’s study

Cholera vaccine supplies dangerously low, outbreaks surging

Medicare isn't yet testing food as medicine

Dario to buy mental health app maker Twill in cash and stock deal

Neuroscience renaissance leads to new crop of psychiatric drugs

Mifepristone protocols being wielded by pill's opponents in Supreme Court case

focus

focus

knowledge

Wikipedia